Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Glaukos Corporation (NYSE: GKOS) announced its management will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:00 a.m. PST. Investors can access a live and archived webcast on the company's website. Glaukos focuses on innovative therapies for glaucoma and other ophthalmic conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent® devices launched since 2012. The company's technology aims to transform glaucoma treatment and enhance corneal health through specialized pharmaceuticals and surgical therapies.
- Participation in a prestigious healthcare conference enhances visibility and credibility.
- Focused on innovative therapies, which may attract investor interest.
- Pioneered MIGS, demonstrating leadership in glaucoma treatment.
- None.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent inject W device in the United States in October 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005006/en/